Urbain Weyemi

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

This study identifies PRDX1's role in preventing oxidative damage to the nucleolar genome by maintaining rDNA transcription and ribosome biogenesis.

This study evaluates SIRT1 inhibition's effect on granulosa cell tumor growth and metastasis using in vitro and in vivo models, finding reduced tumor progression with EX-527 treatment.

The paper identifies MPC1 as a key driver of PARP inhibitor resistance in NSCLC lung cancer through a metabolism-focused CRISPR screen.